Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

You may not be if

• 1. Patients must complete Stage 2 of the core study B2335S (NCT00463567).
• 2. Written informed consent to participate in the extension must be obtained.
• 3. Patients must be able to comply with all study requirements.
• Patients who were randomized to open-label tiotropium in Study B2335S.
• Patients who participated in Stage 1 of the core study (B2335S).
• Patients discontinued irrespective of the reason from Stage 2 of the core study.
• Patients who fail to comply with the core protocol requirements and procedures.
• Concomitant medical conditions that may interfere with interpretation of study results as defined in the core study protocol.
• Patients who in the Investigator's opinion should not participate in the extension study.